secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aquestive Therapeutics, Inc. (AQST)
CIK:        0001398733
Form:       8-K
Filed at:   2024-11-04T23:59:59+00:00
Accession:  0001628280-24-045028
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aquestive Q3 net loss $11.5M vs $2.0M; revenue up 4% to $13.5M; Anaphylm pre-NDA meeting in Q4
--------------------------------------------------------------------------------

- Total revenues $13.5M (+4% YoY); net loss $11.5M ($0.13/sh) vs $2.0M loss in Q3 2023.
- Cash $77.9M; FY2024 guidance: revenue $57-60M, adj EBITDA loss $20-23M.
- Anaphylm pre-NDA meeting with FDA scheduled Q4 2024; NDA submission targeted Q1 2025, launch Q1 2026 if approved.
- AQST-108 (epinephrine topical gel) pre-IND meeting Q4 2024; Phase 2a in alopecia areata planned Q2 2025.
- Libervant launched for ages 2-5 with dedicated sales force; commercial and Medicaid coverage expanded nationwide.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1398733/000162828024045028/0001628280-24-045028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1398733/000162828024045028/aqst-20241104.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-045028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer